スコットランドリーグ放送
<ウェブサイト名>
<現在の時刻>
If Javascript is turned off, turn it on. Purpose Impact Domains Drivers Open Search Open Profile Investors Careers Newsroom Contact Us JP EN Open Search Open Products Information Search Close JP EN Purpose Impact Domains Drivers Profile Investors Careers Newsroom Contact Us Using this Website Privacy Policy Site Map Products Information Close Purpose Purpose Impact Domains Drivers Profile Investors Newsroom Purpose Message from Top Management CSV Purpose Long-term Management Vision and Medium-Term Business Plan KIRIN’s HISTORY Corporate Governance Risk Management Value Creation Model About Kirin Group Impact The Origin and Progress of CSV Management CSV Management Management Issues for Sustainable Growth (Group Materiality Matrix) A Responsible Alcohol Producer Health and Well-Being Community Engagement Respect for human rights The Environment Other material agenda and governance Domains Product brands Food & Beverages Health Science Pharmaceuticals Drivers Core technology that assures value creation Consumer centric marketing ICT accelerating value creation Diversity and inclusion, culture for innovation Financial strategy Profile Corporate Policy Corporate Overview Management Group Companies Company History Our Approaches in Quality Investors Management Policy Chart Generator Financial Data Non-Financial Information Share-related Information IR Library Individual Investors IR Events Calendar IR website user guide Disclaimer FAQs Third-Party Evaluations Newsroom News Releases Media kit Media Contacts Long-term Management Vision and Medium-Term Business Plan Management Plan Releases and Presentations Value Creation Model Value Creation Story Corporate Governance Overview Management Structure Management, Leadership & Advisory Remuneration System for Executive Officers Risk Management Compliance Kirin Group Tax Policy CSV Management 2022-2024 CSV Commitments Establishment and Operation of the Group CSV Committee Group Sustainability Meetings on Specific Issues Stakeholder Engagement Endorsement and participation in external organizations and initiatives United Nations Global Compact Policies Social contribution activities Sustainable Finance Marketing Communication Policy(MCP) Health and Well-Being What is “Health & Well-being” in Kirin Group? Ensuring food safety and security Ensuring stable supply, safety and reliability as a pharmaceutical company Provide pharmaceuticals for Unmet Medical Needs Support for maintaining the immune system Ensuring occupational health and safety Support for the prevention of non-communicable diseases Implementation of health management Helping to improve the performance of brain function and prevent decline Improvement of access to nutrition Community Engagement Respect for human rights Sustainable development of communities in raw material production areas and business development regions Creating bonds and trust for people's well-being Enhancing the sustainability of food economy Sustainable supply chain Community Topics Respect for human rights Kirin Group Human Rights Policy Embedding the Kirin Group Human Rights Policy in practice Implementing Human Rights Due Diligence The Environment Sustainable use of biological resources Sustainable use of water resources Sustainable recycling of containers and packaging Overcoming climate change Kirin Group's Environmental Vision 2050 Message from Top Management Engagement Vision / Policies / Structure Environmental management and CSV Holistic Environmental Management Information Disclosure Based on the TCFD Framework, TNFD Framework Draft, etc. Our Holistic Approach Third-Party Evaluations of environment Environmental Topics A Responsible Alcohol Producer Dealing with alcohol-related problems Policy and System Food and Beverages Kirin Brewery Company, Limited Lion Pty Ltd Kirin Beverage Company, Limited Mercian Coca-Cola Beverages Northeast, Inc. Health Science domain Message from Senior Executive Officer of Health Science Strategy Kirin Holdings Company, Limited Kyowa Hakko Bio Co., Ltd. Koiwai Dairy Products Co., Ltd. Kirin Beverage Company, Limited Core technology that assures value creation Accelerating intellectual property activities that leverage technological capabilities for the business Diversity and inclusion, culture for innovation Strengthening the human capital capability Diversity Cultivating the organizational culture Corporate Policy Achieving "Joy brings us together" The Story Behind Kirin Beer Labels Corporate Overview Barrier-free route to Kirin Group Head Office Group Companies Kirin Brewery Company, Limited Kirin Beverage Company, Limited Mercian Corporation Company History 1885‐1949 1950‐1989 1990‐1999 2000‐2009 2010‐2019 2020‐ Our Approaches in Quality Quality management Ensuring Product Safety and Reliability in the Food & Beverages Domain Ensuring Product Safety and Reliability in the Health Science Domain Chart Generator Yearly Data Quarterly Data Management Policy Corporate Disclosure Policy Financial Data Message from the Chief Financial Officer Management Analysis Of Financial Position, Operating Results, And Cash Flows Business Segments Consolidated Balance Sheets Consolidated Statements of Income Statements of Cash Flows Non-Financial Information Message from Senior Executive Officer of CSV Strategy ESG Databook Guideline Content Index Share-related Information General Meetings of Shareholders Dividend Payments and Own-share Repurchase Stock Information Share Data Stock Quote Bonds and Rating Analyst Coverage Articles of Incorporation and Regulations Public Notice IR Library Financial Results（Financial Results/Presentations/Financial Statements） IR News Releases IR Events Releases and Presentations Archive Integrated Report Investor’s Guide Market data and Sales Kirin Group Environmental Report Management Plan Releases and Presentations Long-term (Archive) Medium-term (Archive) Current Fiscal Year (Archive) Management Structure Interview with Independent Non-executive Directors 2022-2024 CSV Commitments 2019-2021 CSV Commitments Social contribution activities The Pink Ribbon Activity JICA-KIRIN Fellowship Program Marketing Communication Policy(MCP) Guidelines of Product Labeling Respect for human rights Kirin Group Human Rights Policy Embedding the Kirin Group Human Rights Policy in practice Implementing Human Rights Due Diligence Sustainable development of communities in raw material production areas and business development regions Japanese hops Tea Leaves Vineyards Sustainable supply chain Policy on Sustainable Procurement Activities to Promote Sustainable Procurement Working Together with Suppliers Engagement Dialogue 01 Dialogue 02 Dialogue 03 Dialogue 04 Dialogue 05 Holistic Environmental Management Information Disclosure Based on the TCFD Framework, TNFD Framework Draft, etc. Risks and Opportunities Dealing with alcohol-related problems What is Slow Drinking? Other initiatives in Japan Business Segments Year Quarter Consolidated Balance Sheets Year Quarter Consolidated Statements of Income Year Quarter Statements of Cash Flows Year Quarter General Meetings of Shareholders Previous Fiscal Years Financial Results（Financial Results/Presentations/Financial Statements） Archive IR Events Releases and Presentations Archive KIRIN R＆D DAY 2020 Archive Integrated Report Integrated Report PDF Kirin Integrated Report 2023 Kirin Integrated Report 2022 Kirin Integrated Report 2021 KIRIN CSV REPORT 2020 KIRIN CSV REPORT 2019 KIRIN REPORT 2018 KIRIN REPORT 2016 KIRIN REPORT 2015 Annual Reports (Back numbers) Market data and Sales Domestic sale outline report(Monthly) Domestic Monthly sales report(Archive) Domestic Alcohol market data(Year) Beer consumption by region(Year) Beer consumption by country(Year) Domestic Soft drink market data(Year) Kirin Group Environmental Report Archive Kirin Group Human Rights Policy Feedback from stakeholders during the establishment of the 2018 Human Rights Policy Activities to Promote Sustainable Procurement Past Reports on human rights impact assessments of supply chains JICA-KIRIN Fellowship Program Greetings from the Host Institution Representatives Overview Fellow Introduction About United Nations University-Kirin Fellowship KIRIN CSV REPORT 2020 Message from Top Management Past and Present Special Feature: Growth Strategies for the Health Science Domain Strengthening Organizational Capabilities Financial and Non-financial Highlights Message from the Chief Financial Officer Interview with the Non-executive Director KIRIN CSV REPORT 2019 Message from Top Management Interview with the Chief Financial Officer Strengthening Our Non-Financial Assets CSV Stories CASE1 Pharmaceuticals business CSV Stories CASE2 Businesses bridging Pharmaceuticals and Food & Beverages CSV Stories CASE3 Community Engagement CSV Stories CASE4 The Environment CSV Stories CASE5 A Responsible Alcohol Producer Discussion with Management Interview with an Outside Director Financial and Non-financial Highlights Past and Present KIRIN REPORT 2018 Message from Top Management Discussion with Management, Part1 Discussion with Management, Part2 Interview with an Outside Director CASE1 Kirin Ichiban Shibori Relaunch and Craft Beer Market Development CASE2 Pharmaceuticals for Worldwide Markets CASE3 Lactococcus lactis strain Plasma Stars in New Products CASE4 Advanced High-Efficiency Facilities at Myanmar Brewery History of the Kirin Group The Kirin Group Today Overview by segment and business for fiscal 2017 Management's discussion & analysis Financial & Non-Financial Highlights KIRIN REPORT 2016 To Our Stakeholders Long-Term Management Vision and Medium-Term Business Plan CFO’s Message Overview of the Kirin Group’s Business Kirin’s Foundation for Value Creation Interview with an Outside Director KIRIN REPORT 2015 KEY POINTS ABOUT KIRIN Long-Term Management Vision and Medium-Term Business Plan KIRIN’S GROWTH STRATEGIES A Conversation between Outside Directors Management Issues for Sustainable Growth (Group Materiality Matrix) Technology (R&D) Foundation SCM Foundation Human Resources Foundation Fellow Introduction 2019 Fellow Researchers and Research Themes 2018 Fellow Researchers and Research Themes 2017 Fellow Researchers and Research Themes About United Nations University-Kirin Fellowship List of Former United Nations University-Kirin Fellows Special Feature: Growth Strategies for the Health Science Domain Strategic Decisions in 2019 / Message from the Officer in Charge of Health Business Strategy Part1 Interview with the Executive Officer of R&D Strategy Part2 Creating Synergies with FANCL Corporation Strengthening Organizational Capabilities Enhancing Kirin Beverage's marketing capabilities Development of our human resources Strengthening Our Non-Financial Assets Honkirin and our marketing reform R&D Strategy:Technology creating trusted value Human resources strategies:Diversity and inclusion, culture for innovation Financial & Non-Financial Highlights Financial Highlights Non-Financial Highlights To Our Stakeholders Kirin’s Management Environment,Vision, and Strategies Progress with the Medium-Term Business Plan Issues and Future Initiatives Aiming to Be a Company That Is Completely Trusted Long-Term Management Vision and Medium-Term Business Plan Long-Term Management Vision Medium-Term Business Plan Recognizing the Challenges and Future Initiatives Kirin’s Foundation for Value Creation The Kirin Group’s Value Creation Marketing Research & Development Supply Chain KEY POINTS ABOUT KIRIN Business Structure / Earnings Structure Kirin's History of Progress Long-Term Management Vision and Medium-Term Business Plan Long-Term Management Vision Medium-Term Business Plan List of Former United Nations University-Kirin Fellows 2016 Fellow's Research Projects 2015 Fellow's Research Projects 2014 Fellow's Research Projects 2013 Fellow's Research Projects 2012 Fellow's Research Projects 2011 Fellow's Research Projects 2010 Fellow's Research Projects 2009 Fellow's Research Projects Close [ここから本文です。] Home Investor Relations IR Library Integrated Report KIRIN CSV REPORT 2019 Past and Present Print Past and PresentCreating an optimal business portfolio in response to changes in the operating environment Building a unique business portfolio spanningfrom Food & Beverages to Pharmaceuticals Kirin Brewery Company A wealth of technologies applied to strengthen pharmaceuticals and bio-chemicals businesses Expanding globally through mergers and acquisitions Building a unique business portfolio spanning from Food & Beverages to Pharmaceuticals The Kirin Group has been able to flexibly adapt to changes in society and the marketplace throughout its history. In the 1950s, when demand for beer was on the rise in Japan in tandem with the country’s rapid economic growth, Kirin Brewery Co., Ltd., succeeded in greatly expanding its beer production, sales, and shipments. By 1972, the company had secured a domestic market share of about 60% for Kirin brand beer, produced by its network of 12 breweries nationwide.Leveraging its ability to adapt and respond to new market trends and consumer needs, the Group established Kirin Beverage Company, Ltd., in 1963, which went on to expand the soft drink business. Then in 1972, the Group launched its whiskey business with the establishment of the forerunner to Kirin Distillery Co., Ltd. Later, the Kirin Group created its first long-term management vision in 1981, through which it setclear goals for continuous growth and proceeded to further diversify its business portfolio. Diversification included entry into the life sciences market, which was projected to grow over the medium and long terms, Kyowa Hakko Kirin Co., Ltd.(Current Kyowa Kirin Co., Ltd.), in 2008. Through this steady expansion, the Kirin Group has continued to offer new value to consumers while building a unique business portfolio spanning from beverages to pharmaceuticals. ColumnKirin Brewery Company founded in 1907 amid intense competition in Japan’s beer industry Japan Brewery Co., Ltd., was set up in 1885 by a number of foreign residents in Yokohama’s Yamate district, who envisioned great promise for a beer industry in Japan. To produce a genuine German-style beer that suited the tastes of Japanese consumers, they imported ingredients and brewing equipment from Germany and hired a qualified German brewmaster. Kirin Beer was sold in 1888 with a label featuring a kirin, a legendary creature from ancient Chinese myths that is said to be a harbinger of good luck. When Japan’s beer industry entered a time of intense competition after the turn of the century, a group representing the Iwasaki family and the companies Mitsubishi and Meidi-Ya took over Japan Brewery and, while leaving the brewery’s operations intact, established Kirin Brewery Company in 1907. One year after the product launch, the original label of Kirin Beer was redesigned as this label in 1889, which features a larger image of the kirin. This label remains as the prototype for the Kirin Lager Beer label used today. A wealth of technologies applied to strengthen pharmaceuticals and bio-chemicals businesses Drawing on bio-technology to break into the pharmaceutical business In 1981, as part of its first long-term management vision,the Kirin Group set out to expand its business into style-,health-, and culture-related markets, and to contribute to people’s quality of life through its products, especially beer, in the lifestyle industry. By proactively promoting more diversified operations, the Group worked to create a more balanced business portfolio that was less reliant on its beer business, and forged a clear roadmap for improving profitability. Guided by its long-term management vision, the Group stepped up efforts to launch new businesses utilizing its expertise in bio-technology, which was accumulated over many years in fermentation and cell cultivation operations. Leveraging those technological capabilities, the Group made advances in drug development, for which market growth was projected over the medium to long terms, and further expands into the life sciences market. ESPO® launched as the first pharmaceutical product through a mutually beneficial partnership with U.S.-based Amgen The Group made a major step forward in its efforts to expand the pharmaceutical business in 1984, when it formed a partnership with the U.S.-based biotech company Amgen, Inc., a venture firm at that time. Combining Amgen’s leading R&D capabilities with Kirin’s manufacturing techniques, the partnership succeeded in mass producing human erythropoietin. That led to the launch of their first pharmaceutical product in 1990: ESPO®, a treatment drug mainly for renalanemia. Incredibly, the drug was commercialized after only six years since forming the partnership, demonstrating Kirin’s entrepreneurial spirit and achievement for wellcollaborated work with the partner. On the momentum of that success, the Group continued to apply its bio-technologies in drug discovery and development. Its pharmaceutical business expanded as a result, and accounted for about 10% of consolidated operating profit in 2007. Accelerating outstanding growth in the pharmaceuticals business and cultivating new Health Science business In 2007, Kirin Pharma Co., Ltd., was established following the Group’s adoption of a pure holding company framework and establishment of Kirin Holdings Co., Ltd. Kirin Pharma then merged with Kyowa Hakko Kogyo Co., Ltd., in 2008 to form Kyowa Hakko Kirin Co., Ltd., and has been creating new pharmaceuticals by leveraging the synergies of the two companies’ antibody- and bio-related technologies. One of the accomplishments of this business came in2018 with the approval and launch of Crysvita, a treatment drug for X-linked hypophosphatemia, in Europe and the United States. Guided by Kirin Group Vision 2027, KyowaHakko Kirin is aiming to take the next major step toward becoming a global specialty pharmaceutical company, while the Group is working to cultivate new businesses bridging Pharmaceuticals and Food & Beverages. Expanding globally through mergers and acquisitions The Kirin Group has been expanding its operations internationally by actively pursuing mergers and acquisitions, focusing on Asia and Oceania in particular as key markets. Subsidiaries around the world are now helping drive the Group’s growth as a whole, including Lion Pty Ltd, an operator of alcoholic and non-alcoholic beverages businesses in Australia, and Myanmar Brewery Ltd. Meanwhile, Kyowa Kirin is striving to develop global pharmaceuticals by drawing on a wealth of bio-technologies. The Kirin Group around the world Alcoholic and non-alcoholic beverages businesses &＃9312;Myanmar Brewery Limited
